Psychopharmacology bulletin最新文献

Parental Involvement in Intervention for Autism Spectrum Disorder: Experiences of Rehabilitation Professionals. 父母参与自闭症谱系障碍的干预：康复专业人员的经验。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20770

Ammu Elizabeth Alexander, P Padmakumari, Sharmili Chatterjee

{"title":"Parental Involvement in Intervention for Autism Spectrum Disorder: Experiences of Rehabilitation Professionals.","authors":"Ammu Elizabeth Alexander, P Padmakumari, Sharmili Chatterjee","doi":"10.64719/pb.20770","DOIUrl":"10.64719/pb.20770","url":null,"abstract":"There has been an increase in the incidence of Autism Spectrum Disorder (ASD) over recent years, which has given rise to an immediate increase in demand for quality intervention and trained professionals. Parental involvement is necessary for a more effective parental training, which will ensure a realistic understanding of their child's difficulties. Previous studies continuously prove that parental involvement in the lives of their children with ASD is beneficial to improvement in their children with ASD. There are no studies that illustrate the challenges that professionals face when trying to involve parents into the intervention. Based on the literature review, it can be projected that an understanding of these factors will help professionals to improvise on strategies to implement parental involvement methods with efficiency and maximize the gains of the individuals with ASD. This study aims to understand the benefits and challenges of rehabilitation professionals in involving parents for treatment of children with ASD, in the manner in which these issues were overcome. Ten professionals (2 from each domain of rehabilitation) were selected to be part of the study. The participants were interviewed using a semi-structured interview questions and the data collected was thematically analysed under the light of Review of Literature. The results of the study clearly show the inevitability of parental involvement in intervention for autism. The study identified five themes: Dual model of Work, Parenting, Socio-cultural Factors, Professional Expertise of Therapist and Limitations with involvement. The present study implies that is important to take the parents' personal psychological challenges into consideration before involving them in intervention. A program that can specifically target the needs of the parent and provide them with the kind of support and knowledge that is necessary for their child can do wonders.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 4 Suppl 1","pages":"57-81"},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Olanzapine-Induced Rapid Weight Gain and Metabolic Disorders: A Case Series. 奥氮平引起的快速体重增加和代谢紊乱：一个病例系列。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20785

Michal Smogur, Séverine Crettol, Céline Dubath, Frederik Vandenberghe, Georgios Schoretsanitis, Philippe Conus, Chin Bin Eap, Nicolas Ansermot

引用次数: 0

Common Pain Medications: Indications, Efficacy, Dosing, Formulations, Mechanisms of Action, and Contraindications. 常见止痛药：适应症、疗效、剂量、配方、作用机制和禁忌症。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20767

Ahmed I Anwar, Riley K Noble, Kyle B Jenks, Sahar Shekoohi, Jamal Hasoon, Omar Viswanath, Ivan Urits, Alan D Kaye

引用次数: 0

Rechallenge after Clozapine-Induced Neutropenic Events: A Case Series. 氯氮平诱导的中性粒细胞减少事件后的再挑战：一个病例系列。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20782

Sumeet Gupta, Mohamed Ismail, Aysha Zabin, Avni Agrawala

引用次数: 0

Gabapentin-Induced Severe Vivid Nightmares: A Case Series and Brief Review. 加巴喷丁诱导的严重生动噩梦：一个案例系列和简要回顾。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20779

Jamal Hasoon, Anvinh Nguyen, Negaar Ada Safabakhsh, Omar Viswanath, Christopher L Robinson

引用次数: 0

Peripheral Inflammatory Biomarkers as Predictors of Antidepressant Treatment Response in Major Depressive Disorder: An Updated Systematic Review and Meta-Analysis. 外周炎症生物标志物作为重度抑郁症抗抑郁治疗反应的预测因子：最新的系统综述和荟萃分析。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20776

Ho Won Chun, Yeong Eun Park, Ju Hwan Kim, Min Chul Park

{"title":"Peripheral Inflammatory Biomarkers as Predictors of Antidepressant Treatment Response in Major Depressive Disorder: An Updated Systematic Review and Meta-Analysis.","authors":"Ho Won Chun, Yeong Eun Park, Ju Hwan Kim, Min Chul Park","doi":"10.64719/pb.20776","DOIUrl":"10.64719/pb.20776","url":null,"abstract":"Rationale: Peripheral inflammatory biomarkers are potential predictors of antidepressant response in major depressive disorder (MDD).Objective: This study updated a 2022 meta-analysis by extending the literature through January 2026 to clarify these biomarker-response associations.Methods: PubMed was searched from February 2021 to January 2026. Eligible studies evaluated baseline peripheral biomarkers in adults with MDD before starting ⩾4 weeks of pharmacotherapy, comparing responders vs. non-responders. Standardized mean differences (SMD; Hedges' g) were pooled using random-effects models. Subgroup analyses and meta-regressions examined antidepressant class and publication period.Results: Twenty-four studies (16 from the prior review, 8 new) were quantitatively analyzed. In primary pooled analyses, no baseline biomarkers (including CRP and IL-8) significantly differentiated responders from non-responders. However, exploratory analyses revealed a nominal interaction by publication period for IL-2 (p = 0.0112). In recent studies (2021-2026), baseline IL-2 was nominally lower in responders than non-responders (SMD = -0.81; 95% CI -1.59 to -0.03; p = 0.04). Similarly, in recent studies restricted to Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-norepinephrine reuptake inhibitors (SNRIs), baseline IL-6 was nominally lower among responders (SMD = -0.37; 95% CI -0.69 to -0.05; p = 0.02). Leave-one-out analyses confirmed overall robustness, though IL-6 showed moderate sensitivity.Conclusion: While individual baseline biomarkers have limited utility as standalone predictors when pooling all historical data, lower baseline IL-2 and IL-6 emerge as promising signals for predicting treatment response in contemporary studies (2021-2026) and specific antidepressant classes (SSRIs/SNRIs).","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 4 Suppl 1","pages":"88-107"},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Auvelity (Dextromethorphan-Bupropion) for Agitation and Aggression in Alzheimer's Disease Dementia: Mechanism, Efficacy, Safety, and Clinical Considerations. Auvelity（右美沙芬-安非他酮）治疗阿尔茨海默病痴呆患者的躁动和攻击：机制、疗效、安全性和临床考虑。

Psychopharmacology bulletin Pub Date : 2026-09-18 DOI: 10.64719/pb.20773

Mridul Sarangal, Charmi Sarangal, Jay Vora, Karishma Soni

{"title":"Auvelity (Dextromethorphan-Bupropion) for Agitation and Aggression in Alzheimer's Disease Dementia: Mechanism, Efficacy, Safety, and Clinical Considerations.","authors":"Mridul Sarangal, Charmi Sarangal, Jay Vora, Karishma Soni","doi":"10.64719/pb.20773","DOIUrl":"10.64719/pb.20773","url":null,"abstract":"Background: Agitation and aggression in Alzheimer's disease (AD) are highly distressing behavioral symptoms traditionally managed with off-label atypical antipsychotics, despite boxed warnings for increased mortality in elderly patients. The emergence of Auvelity (dextromethorphan-bupropion) provides a critical, non-antipsychotic therapeutic alternative.Mechanism: This combination utilizes bupropion as a CYP2D6 inhibitor to achieve therapeutic central nervous system concentrations of dextromethorphan. Dextromethorphan acts as an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, bypassing dopaminergic blockade to promote synaptic plasticity via glutamatergic and monoaminergic modulation.Efficacy: Key clinical trials (ADVANCE-1 and ACCORD) demonstrate that dextromethorphan-bupropion produces rapid, statistically significant reductions in Cohen-Mansfield Agitation Inventory (CMAI) scores. Furthermore, it offers robust long-term maintenance, demonstrating a 3.6-fold lower risk of agitation relapse compared to placebo.Safety: The combination therapy was generally well-tolerated in trials, successfully avoiding the sedation, cognitive blunting, and heightened fall risks characteristic of antipsychotics. Clinicians must, however, monitor for blood pressure changes and potential CYP2D6 drug-drug interactions.Conclusion: Dextromethorphan-bupropion represents a highly efficacious, safer paradigm shift in the pharmacological management of AD-associated agitation, offering targeted symptom relief while minimizing the severe risks associated with standard antipsychotic use.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 4 Suppl 1","pages":"82-87"},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychopharmacology of Eugeroics-The Whole Nine Yards! 优生学的精神药理学——整整九码！

Psychopharmacology bulletin Pub Date : 2026-06-05 DOI: 10.64719/pb.18552

Ahmed Naguy, Hend F Alenezi

引用次数: 0

Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update. 重度抑郁症的循证药物治疗：临床最新进展。

Psychopharmacology bulletin Pub Date : 2026-06-05 DOI: 10.64719/pb.18522

Matheus G Marques, Balwinder Singh

{"title":"Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update.","authors":"Matheus G Marques, Balwinder Singh","doi":"10.64719/pb.18522","DOIUrl":"10.64719/pb.18522","url":null,"abstract":"Major Depressive Disorder (MDD) represents the classically described episodic depression, with varying degrees of severity and recurrence. With a lifetime prevalence close to 20%, the condition represents a leading cause of disability worldwide. Pharmacotherapy is an option for initial treatment, especially in cases of higher severity. As over half of patients will not experience remission after first antidepressant trial, it is essential for clinicians to understand the vast number of medications available and their unique characteristics. This review provides a comprehensive clinical update on evidence-based pharmacotherapies for MDD, including both established and novel treatment options. Traditional monoaminergic antidepressants remain as important options with comparable efficacy but often distinct side-effect profile. Augmentation strategies are often employed with partial treatment response and are available with a wide range of mechanisms and unique clinical nuances. Fast-acting agents are now a reality in practice, including neuroactive steroids for postpartum depression and agents that target glutamatergic pathways. Relevant aspects for clinical practice are provided for over forty different medications, presenting dose ranges, adverse effects, monitoring requirements, and important patient characteristics to consider when prescribing. We also highlight concepts important for successful pharmacotherapy such as accurate diagnosis and treatment resistance. With the expanding therapeutic arsenal for MDD, ongoing comparative-effectiveness and real-world studies will be crucial for transforming today's advances into accurately personalized care.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 3","pages":"82-108"},"PeriodicalIF":0.0,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13244322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Care Becomes Dangerous: Patient Assaults Against Physicians. 当护理变得危险：病人对医生的攻击。

Psychopharmacology bulletin Pub Date : 2026-06-05 DOI: 10.64719/pb.18555

Madelyn Reilly, Jamal Hasoon, Alaa Abd-Elsayed

引用次数: 0